PDF herunterladen
Horm Metab Res 1990; 22(12): 627-631
DOI: 10.1055/s-2007-1004989
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Effect of Somatostatin on TSH Levels in Non-Toxic Sporadic Goiter

J. Varea1 , M. Paredes1 , G. Garces1 , C. Ochoa1 , C. Avila1 , M. J. Coloma1 , R. Briones1 , A. M. Comaru-Schally2 , A. V. Schally2
  • 1Endocrine Service, Carlos Andrade Marin Hospital, Ecuadorian Social Security Institute, and Ciencia Foundation for the Study of Man and Nature, Quito, Ecuador
  • 2Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, Louisiana, U. S. A.
Weitere Informationen

Publikationsverlauf

1989

1990

Publikationsdatum:
14. März 2008 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Somatostatin (SS-14; growth hormone-release inhibiting hormone) was infused into eight patients with non-toxic sporadic goiter and into eleven normal control subjects. Each patient was given 150 μg of Somatostatin as an intravenous bolus and 350 μg by infusion over a period of 60 minutes. Somatostatin did not lower the basal TSH levels as compared to the pre-infusion levels in this type of goiter, but produced a decrease in the TSH response to TRH during and after the infusion.

Key words

Goiter - Somatostatin - TRH - TSH